These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 34349500)

  • 21. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric Oxide Stimulated Programmable Drug Release of Nanosystem for Multidrug Resistance Cancer Therapy.
    Wang L; Chang Y; Feng Y; Li X; Cheng Y; Jian H; Ma X; Zheng R; Wu X; Xu K; Zhang H
    Nano Lett; 2019 Oct; 19(10):6800-6811. PubMed ID: 31466437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk.
    Bhattacharjee M; Ghosh A; Das S; Sarker S; Bhattacharya S; Das A; Ghosh S; Chattopadhyay S; Ghosh S; Adhikary A
    ACS Biomater Sci Eng; 2024 Oct; 10(10):6314-6331. PubMed ID: 39285678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of Chemoresistance via Staged Liberation of Chemodrug and siRNA in Hierarchical Response to ROS Gradient.
    Dang J; Li Y; Yan J; Wu J; Cai K; Yin L; Zhou Z
    Adv Healthc Mater; 2024 Jun; 13(15):e2304130. PubMed ID: 38427696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model.
    Yang Y; Yang S; Zhang B; Wang J; Meng D; Cui L; Zhang L
    Int J Nanomedicine; 2024; 19():8949-8970. PubMed ID: 39246424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation.
    Zhu C; Guo X; Luo L; Wu Z; Luo Z; Jiang M; Zhang J; Qin B; Shi Y; Lou Y; Qiu Y; You J
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46536-46547. PubMed ID: 31751119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
    Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
    ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
    Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
    FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
    Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
    Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
    [No Abstract]   [Full Text] [Related]  

  • 35. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
    Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
    [No Abstract]   [Full Text] [Related]  

  • 38. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance.
    Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D
    Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.